Company ProfileSarepta Therapeutics remains focused on developing first-in-class RNA-based therapies to improve and save the lives of people affected by rare and infectious diseases. Our commitment is to translate our unique RNA-based technology into therapeutics for serious and life-threatening genetic-based diseases.
Our diverse pipeline of RNA-based therapies have yielded our lead program, eteplirsen, for Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases. We hav... More >> | | Stock Information |
|
Recent Press Releases| 05/10/13 | Sarepta Therapeutics to Present Company Overview at Upcoming Conferences| Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (Marketwired) -- 05/10/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in May. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 8:30 a.m. Eastern Time.
Deutsche Bank's 38th Ann... |
|  | | 05/09/13 | Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments| Documents Requested by FDA for Accelerated Approval Consideration of Eteplirsen Will Be Submitted This Month; Clinical, Regulatory, and Manufacturing Activities Continue to Progress for Eteplirsen and Additional Duchenne Muscular Dystrophy Drug Candidates; Strong Cash Balance of $175 Million at Quarter-End
CAMBRIDGE, MA -- (Marketwired) -- 05/09/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three mont... |
| | | 05/07/13 | Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus| CAMBRIDGE, MA -- (Marketwired) -- 05/07/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has initiated dosing in a Phase 1 multiple ascending dose (MAD) clinical trial of AVI-7288, the Company's lead drug candidate for the treatment of Marburg virus infection. The Phase I MAD study is designed to characterize the safety, tolerability and pharmacokinetics of AVI-7288 after repeat dosing in healthy adult volunteers. The in... |
| | | 04/26/13 | Sarepta Therapeutics to Announce First Quarter 2013 Financial Results and Corporate Update on May 9, 2013| CAMBRIDGE, MA -- (Marketwired) -- 04/26/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report first quarter financial results before the NASDAQ Global Market opens on Thursday, May 9, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's President and CEO, will host a conference call to discuss first quarter financial results and to provide a corporate update.
The conference call may be acc... |
| |
|
More Releases
In the News | October 22, 2012 |
|  | | Recent Coverage | Written by Miriam Metzinger October 4, 2012 | Written by Brian Wilson October 4, 2012 | Written by Matthew Smith October 4, 2012 |
|  | Written by Mandy Jackson October 4, 2012 |
|  | | Recent Coverage | October 4, 2012 | Written by Randy Osborne October 4, 2012 | October 3, 2012 |
|  October 3, 2012 |  | | Recent Coverage | Written by Brenton Flynn October 3, 2012 | Written by Dave Williamson October 3, 2012 |
|  October 3, 2012 |  | October 3, 2012 |
|  | | Recent Coverage | Written by Matthew Herper October 3, 2012 | Written by Matthew Herper October 3, 2012 |
|  | Written by Adam Feuerstein October 3, 2012 |
|  | Written by Andrew Pollack October 3, 2012 |
|  | Written by Anna Edney October 3, 2012 |
|  | Written by Tess Stynes October 3, 2012 | Written by Joseph Walker October 3, 2012 |
|  | | Recent Coverage | Written by Andrew Barry October 3, 2012 | August 25, 2012 | April 7, 2012 | April 2, 2012 |
|  Recent Coverage Written by Jessica Merrill October 3, 2012 August 22, 2012 |  | | Recent Coverage | Written by Luke Timmerman Oct 3, 2012 | April 6, 2012 | June 2, 2011 |
|  July 2012 |  June 21, 2012 | | | | Life Sciences Leader
Rare Disease Drug Development: A Thriving Business Model Written by Chris Garabedian, president and CEO, AVI BioPharma June 1, 2012 |  October 19, 2011 |  Sep 13, 2011 |  King5 Healthlink
Chris Garabedian, CEO and Patrick Iversen, PhD,
Senior Vice President of Research and Innovation
September 8, 2011 |  Chris Garabedian, CEO AVI BioPharma
June 10, 2011 |  The New Yorker
Jan. 31, 2011 |  September 12, 2001 | | | | | |
 |
Upcoming Events| 05/21/13 8:30 a.m. ET | | | 05/30/13 2:50 p.m. ET | |
|
More Events |
